Visited : 704
An iron-oxide nanoparticle that is FDA-approved to treat anemia acts as an enzyme to activate hydrogen peroxide to suppress the growth of tooth-decay-causing biofilms in the human mouth, according to a study led by the School of Dental Medicine.
Agrowing body of evidence points to a link between iron-deficiency anemia and severe tooth decay. Whether the connection is correlative or causative is unknown, though both conditions are associated with poor diets and are more common in people living in impoverished environments and with underlying medical conditions.
Now, research from the University of Pennsylvania, in collaboration with Indiana University, suggests that an FDA-approved therapy for iron-deficiency anemia also holds promise for treating, preventing, and even diagnosing dental decay. The therapeutic, a combination of an iron-oxide nanoparticle-containing solution called ferumoxytol and hydrogen peroxide, was applied to real tooth enamel placed in a denture-like appliance and worn by the study subjects.
Pairing iron oxide nanoparticles with hydrogen peroxide results in a precisely targeted treatment for killing harmful oral bacteria, breaking down dental plaque, and even diagnosing harmful oral biofilms, according to a new study. (Image: Courtesy of the study authors)
The study, published in the journal Nano Letters, found that a twice daily application of ferumoxytol, which activated hydrogen peroxide contained in a follow-up rinse, significantly reduced the buildup of harmful dental plaque and had a targeted effect on the bacteria largely responsible for tooth decay. These types of nanoparticles with enzyme-like properties are sometimes known as “nanozymes” and are increasingly being explored for their potential in biomedical and environmental applications.
“We found that this approach is both precise and effective,” says Hyun (Michel) Koo, a professor in the University of Pennsylvania School of Dental Medicine. “It disrupts biofilms, particularly those formed by Streptococcus mutans, which cause caries, and it also reduced the extent of enamel decay. This is the first study we know of done in a clinical setting that demonstrates the therapeutic value of nanozymes against an infectious disease.”
The work is an extension of a 2018 paper published in Nature Communications, in which Koo and colleagues, including David Cormode of Penn’s Perelman School of Medicine, showed that the iron oxide nanoparticle-hydrogen peroxide treatment could prevent biofilm accumulation and tooth-decay in an experimental model and an animal model.
In the current work, the scientists wanted to take the next logical step, working in humans. In a randomized study, they had 15 participants use a removable, denture-like device with real tooth enamel attached, a method developed and extensively tested by Domenick T. Zero of Indiana University, a co-corresponding author on the current paper.
The study participants applied a sugar-containing solution to the appliance four times a day, mimicking high-sugar meals and snacks consumed in the course of daily life. Participants were asked not to brush the enamel specimens but instead to rinse the appliance twice a day. Participants were divided into three groups, with one using the ferumoxytol then the hydrogen peroxide rinse, one with a solution that provides the inactive ingredients in ferumoxytol, and a third with water alone.
After 14 days, the researchers analyzed the biofilms that accumulated on the enamel specimens. They found the experimental treatment potently reduced the growth of biofilms containing S. mutans and could kill this bacteria with high specificity. Other commensal bacteria normally found in the mouth were not affected by the ferumoxytol-hydrogen peroxide therapy.
The results and safety of the approach were supported by previous work, which has shown that the iron oxide nanoparticles do not bind to the mucosal tissue in the mouth and do not cause cytotoxicity or changes in the oral microbiome in an animal model.
“This treatment doesn’t seem to have harmful, off-target effects,” Koo says.
The reason for this precision is three-fold. The reaction to catalyze hydrogen peroxide only happens in a highly acidic environment, such as what arises when caries-causing bacteria are present and active. The treatment also causes the sticky matrix of carbohydrates to break down, degrading the biofilm and exposing the microbes. And ferumoxytol can specifically bind to receptors on the S. mutans cell membrane, facilitating its killing.
In a final stage of the study, the researchers added a marker that turns blue when exposed to reactive oxygen species, like those generated by the catalysis of hydrogen peroxide by ferumoxytol nanoparticles. And indeed, the team found that the intensity of blue labeling corresponded with acidic biofilms containing S. mutans.
Because of this “detection” capability, Koo notes that the experimental treatment has the potential to become what is known as a “theranostic,” that is, a drug that can be used to both diagnose a condition and treat it. “It can also be used at home,” Koo says. “You could rinse with it, see how much cavity-causing plaque there is, and then treat with the solution or consult a dentist for follow-up treatment.”
Hyun (Michel) Koo is a professor in the Department of Orthodontics and divisions of Community Oral Health and Pediatric Dentistry at the University of Pennsylvania School of Dental Medicine.
Koo’s coauthors on the paper were Yuan Liu and Zhi Ren of Penn Dental Medicine, Yue Huang and Min Jun Oh of both Penn Dental Medicine and Penn’s Perelman School of Medicine, David Cormode of the Perelman School of Medicine and Penn’s School of Engineering and Applied Science, Dongyeop Kim of Korea’s Jeonbuk National University, and Anderson T. Hara and Domenick T. Zero of Indiana University. Liu was first author and Zero and Koo were co-corresponding authors on the paper.
Read the original article on Penn Today, University of Pennsylvania.